Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: Potential application to melanoma

被引:11
作者
Borden, Ernest C. [1 ]
机构
[1] Cleveland Clin Fdn, Case Comprehens Canc Ctr, Taussig Canc Ctr, Cleveland, OH 44195 USA
关键词
APO2L/TRAIL; azacytidine; apoptosis;
D O I
10.1016/j.cytogfr.2007.06.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increased expression of genes, silenced by methylation of their promoters, could have relevance for increasing effects of not only interferons (IFNs) but also APO2L/TRAIL, cytotoxics and immunotherapeutics for melanoma and other malignancies. A resistant melanoma cell line, A375, lacked APO02L/TRAIL or apoptosis induction by either IFN-alpha 2 or IFN-beta. However, apoptosis was induced by IFNs in A375 cells by 5-aza,2'-deoxycytidine (5-Aza-dC), evaluated based upon the postulate that promoter methylation might be silencing pro-apopoptotic IFN-stimulated genes (ISGs). RASSF1A, commonly methylated at high frequency in many tumors including melanoma, which we discovered to be also an IFN-regulated gene, was increased by 5-Aza-dC. RASSF1 A was important in enhancing apoptotic effects of not only IFNs and APO2L/TRAIL but also cisplatin. Unraveling epigenetic regulatory mechanisms, as yet only partially identified, will result in new biological insights and improved strategies for therapeutic use of IFNs or ISGs such as APO2L/TRAIL. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:491 / 501
页数:11
相关论文
共 118 条
[1]   Role of the ras-association domain family 1 tumor suppressor gene in human cancers [J].
Agathanggelou, A ;
Cooper, WN ;
Latif, F .
CANCER RESEARCH, 2005, 65 (09) :3497-3508
[2]   Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer [J].
Ai, Lingbao ;
Tao, Qian ;
Zhong, Sheng ;
Fields, C. Robert ;
Kim, Wan-Ju ;
Lee, Michael W. ;
Cui, Yan ;
Brown, Kevin D. ;
Robertson, Keith D. .
CARCINOGENESIS, 2006, 27 (07) :1341-1348
[3]   Expression of IFITM1 in chronic myeloid leukemia patients [J].
Akyerli, CB ;
Beksac, M ;
Holko, M ;
Frevel, M ;
Dalva, K ;
Özbek, U ;
Soydan, E ;
Özcan, M ;
Özet, GL ;
Ilhan, O ;
Gürman, G ;
Akan, H ;
Williams, BRG ;
Özçelik, T .
LEUKEMIA RESEARCH, 2005, 29 (03) :283-286
[4]  
[Anonymous], 2003, Cutaneous melanoma
[5]   Phase I trial of continuous infusion 5-aza-2′-deoxycytidine [J].
Aparicio, A ;
Eads, CA ;
Leong, LA ;
Laird, PW ;
Newman, EM ;
Synold, TW ;
Baker, SD ;
Zhao, M ;
Weber, JS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) :231-239
[6]   RESPONSE AND RESISTANCE TO INTERFERONS AND INTERACTING CYTOKINES [J].
BORDEN, EC ;
WAALEN, J ;
SCHREIBER, R ;
WILLIAMS, BY .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (04) :257-264
[7]   Milstein Award Lecture: Interferons and cancer: Where from here? [J].
Borden, EC .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2005, 25 (09) :511-527
[8]  
Borden EC, 1998, SEMIN ONCOL, V25, P1
[9]  
BORDEN EC, 1990, CANCER RES, V50, P1071
[10]  
BORDEN EC, 1982, CANCER RES, V42, P4948